logo

Achillion Pharmaceuticals Inc. (ACHN)



Trade ACHN now with
  Date
  Headline
7/22/2019 7:10:40 AM Achillion’s ACH-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers
4/3/2019 6:06:55 AM Achillion Achieves Threshold Enrollment In Phase 2 Trials Of ACH-4471 For Patients With C3 Glomerulopathy
3/27/2019 6:20:47 AM Achillion Completes Enrollment In ACH-4471 Phase 2 PNH Trial In Combination With Eculizumab
3/7/2019 6:05:57 AM Achillion Pharma Q4 Net Loss $16.6 Mln Vs Loss Of $23.2 Mln Last Year
2/11/2019 6:15:06 AM Achillion Appoints Brian Di Donato SVP And CFO
1/31/2019 6:06:57 AM Achillion Reports First Dosing In Phase 1 Multiple Ascending Dose Study Of ACH-5228
1/3/2019 6:01:45 AM Achillion Names Nicole Vitullo To Chair The Board
11/7/2018 6:12:05 AM Achillion Q3 Net Loss $15.9 Mln Vs Net Loss $19.3 Mln Last Year
9/10/2018 6:00:42 AM Achillion Appoints Paul Firuta To EVP And COO
8/21/2018 6:03:36 AM Achillion Appoints Steven Zelenkofske To Position Of EVP And Chief Medical Officer
8/15/2018 4:08:03 PM Achillion Appoints Anthony Gibney As Chief Business Officer
7/10/2018 6:07:27 AM Achillion Begins Phase I First-in-Human Study Of ACH-5548
5/2/2018 6:41:32 AM Achillion Q1 Net Loss $20.6 Mln Or $0.15/Shr Vs Net Loss $20.2 Mln Or $0.15/Shr Last Year